IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immix Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$8.22+0.24 (+3.01%)
Close on Oct 19, 2026
- Market cap
- $524.20M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$5.35 (+186.4%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $524.20M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.29
- Dividend yield
- –
- Free cash flow yield
- -7.46%
Fundamentals
- Net income
- -$39.88M
- EPS, diluted
- -$0.86
- Free cash flow
- -$39.09M
- Book value per share
- $3.59
- Diluted shares
- 64M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$41.82M
Net income
-$39.88M
EPS, diluted
-$0.86
Free cash flow
-$39.09M
Reported periodTrailing twelve months